BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice

J Physiol Pharmacol. 2007 Sep;58(3):583-8.

Abstract

Recently, we have shown that MK-886 - an inhibitor of five lipoxygenase activating protein (FLAP) inhibits atherosclerosis in apolipoprotein E / LDL receptor - double knockout mice. We, therefore, wanted to find out if other FLAP inhibitor - BAYx1005 given at a dose of 1.88 mg per 100 mg of body weight per day during 16 weeks, could also attenuate atherogenesis. In apoE/LDLR - DKO mouse model BAYx1005 inhibited atherogenesis, measured both by "en face" method (23.84 +/- 2.7% vs. 15.16 +/- 1.4%) and "cross-section" method (497236 +/- 31516 microm(2) vs. 278107 +/- 21824 microm(2)). This is the first report that shows the effect of BAYx1005 on atherogenesis in gene-targeted mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta / drug effects
  • Aorta / metabolism
  • Aorta / pathology
  • Apolipoproteins E / genetics*
  • Apolipoproteins E / metabolism
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / genetics
  • Atherosclerosis / metabolism
  • Azo Compounds / chemistry
  • Female
  • Lipoxygenase Inhibitors / chemistry
  • Lipoxygenase Inhibitors / pharmacology
  • Lipoxygenase Inhibitors / therapeutic use
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Molecular Structure
  • Quinolines / chemistry
  • Quinolines / pharmacology*
  • Quinolines / therapeutic use
  • Receptors, LDL / genetics*
  • Receptors, LDL / metabolism
  • Staining and Labeling / methods

Substances

  • Apolipoproteins E
  • Azo Compounds
  • Lipoxygenase Inhibitors
  • Quinolines
  • Receptors, LDL
  • 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid
  • oil red O